Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes

References

• Rudwaleit M, Landewé R, van der Heijde D, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009;68:770-6
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73
   PubMed Web of Science ®Google Scholar
• Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8
   PubMed Web of Science ®Google Scholar
• Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. In: Annals of the Rheumatic Diseases 2006;65:316-20
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8
   PubMed Web of Science ®Google Scholar
• Sidiropoulos PI, Hatemi G, Song IH, et al. Evidence-based recommendations for the management of ankylosing spondylitis: Systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 2008;47:355-61
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2011(1):4-12
   Google Scholar
• Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6-16
   PubMed Web of Science ®Google Scholar
• Zochling J, Braun J. Assessment of ankylosing spondylitis. Clin Exp Rheumatol 2005;23(Suppl 39):S133-41
   Google Scholar
• Van Tubergen AM, Landewé RBM. Tools for monitoring spondyloarthritis in clinical practice. Nat Rev Rheumatol 2009;5:608-15
   Google Scholar
• Pavy S, Dernis E, Lavie F, et al. Imaging for the diagnosis and follow-up of ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007;74:338-45
   Google Scholar
• Dernis E, Lavie F, Pavy S, et al. Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007;74:330-7
   Google Scholar
• Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 2011;23:339-45
   PubMed Web of Science ®Google Scholar
• Spoorenberg A, van Tubergen A, Landewé R, et al. Measuring disease activity in ankylosing spondylitis: Patient and physician have different perspectives. Rheumatology 2005;44:789-95
   PubMed Web of Science ®Google Scholar
• Barton JL, Imboden J, Graf J, et al. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res 2010;62:857-64
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-18
   PubMed Web of Science ®Google Scholar
• Aydin SZ, Can M, Atagunduz P, Direskeneli H. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: A prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 2010;28:752-5
   Google Scholar
• Machado P, Landewé R. Spondyloarthritis: Is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol 2013;9(7):388-90
   Google Scholar
• Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014;73(8):1455-61
   PubMed Web of Science ®Google Scholar
• Creemers MCW, Franssen MJAM, van’t Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70(1):47-53
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Braun J, Dougados M, et al. Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford) 2012;51(10):1894-905
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, Cruyssen BV, Mulero J, et al. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin 2014;10:204-9
   PubMedGoogle Scholar
• Fagerli KM, Lie E, Van der heijde D, et al. Selecting patients with ankylosing spondylitis for tnf inhibitor therapy: Comparison of ASDAS and basdai eligibility criteria. Rheumatol (United Kingdom) 2012;51:1479-83
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70:973-81
   PubMed Web of Science ®Google Scholar
• Machado P, Landewe RB, Braun J, et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012;71:2002-5
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sørensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011;70:1375-81
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sørensen IJ, Hermann K-GA, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69(6):1065-71
   Google Scholar
• Song IH, Rudwaleit M, Listing J, Sieper J. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 2009;68:1701-7
   Google Scholar
• Eder L, Chandran V, Shen H, et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010;69:2160-4
   PubMed Web of Science ®Google Scholar
• Ramiro S, van Tubergen A, van der Heijde D, et al. How to deal with missing items in BASDAI and BASFI. Rheumatology (Oxford) 2014;53(2):374-6
   Google Scholar
• Stone MA, Pomeroy E, Keat A, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology 2008;47:1213-18
   Google Scholar
• Wanders A, Landewé R, Dougados M, et al. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005;64:988-94
   PubMed Web of Science ®Google Scholar
• Landewé R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863-7
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69:1465-70
   PubMed Web of Science ®Google Scholar
• Brionez TF, Assassi S, Reveille JD, et al. Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. Arthritis Res Ther 2009;11:R182
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44
   PubMed Web of Science ®Google Scholar
• Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise - The INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007;34:1740-5
   Google Scholar
• Ramiro S, van Tubergen A, Stolwijk C, et al. Reference intervals of spinal mobility measures in normal individuals: the mobility study. Ann Rheum Dis 2014;74(6):1218-24
   Google Scholar
• Assassi S, Weisman MH, Lee M, et al. New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Rheumatol (Hoboken, NJ) 2014;66(9):2628-37
   Google Scholar
• Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the bath ankylosing spondylitis functional index. J Rheumatol 1994;21:2281-5
   PubMed Web of Science ®Google Scholar
• Jones SD, Porter J, Garrett SL, et al. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 1995;22(8):1609
   Google Scholar
• Van Der Heijde D, Deodhar A, Inman RD, et al. Comparison of three methods for calculating the bath ankylosing spondylitis metrology index in a randomized placebo-controlled study. Arthritis Care Res 2012;64:1919-22
   Web of Science ®Google Scholar
• Haywood KL, Garratt AM, Jordan K, et al. Spinal mobility in ankylosing spondylitis: Reliability, validity and responsiveness. Rheumatology 2004;43:750-7
   PubMed Web of Science ®Google Scholar
• Van Weely SFE, Dekker J, Steultjens MPM, et al. Objective Evaluation of Physical Functioning after Tumor Necrosis Factor Inhibitory Therapy in Patients with Ankylosing Spondylitis: A Selection of 3 Feasible Performance-based Tests. J Rheumatol 2015;42(4):623-9
   Google Scholar
• Van Weely SF, van Denderen JC, Steultjens MP, et al. Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis. Arthritis Res Ther 2012;14(2):R52
   Google Scholar
• Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2014;74(5):830-5
   Google Scholar
• Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-15
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Golder W, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004;63:1046-55
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:697-735
   PubMed Web of Science ®Google Scholar
• Spoorenberg A, de Vlam K, van der Linden S, et al. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol 2004;31:125-32
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Von Der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis - Evidence for major individual variations in a large proportion of patients. J Rheumatol 2009;36:997-1002
   PubMed Web of Science ®Google Scholar
• Bennett AN, Rehman A, Hensor EMA, et al. Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum 2009;60:1331-41
   Google Scholar
• Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 2013;73(10):1819-25
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Landewé R, Hermann K-G, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005;64:730-4
   PubMed Web of Science ®Google Scholar
• Bennett AN, McGonagle D, O’Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008;58:3413-18
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005;52(4):1216-23
   Google Scholar
• Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36
   PubMed Web of Science ®Google Scholar
• Braun J, Landewe R, Hermann K-GA, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Baraf HSB, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Sivera F, Cawkwell LS, et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009;68:1466-9
   PubMed Web of Science ®Google Scholar
• Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70(6):896-904
   PubMed Web of Science ®Google Scholar
• Dougados M, Béhier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5
   PubMed Web of Science ®Google Scholar
• Barkhuizen A, Steinfeld S, Robbins J, et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006;33:1805-12
   PubMed Web of Science ®Google Scholar
• Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008;67:323-9
   PubMed Web of Science ®Google Scholar
• Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101-7
   PubMed Web of Science ®Google Scholar
• Wanders A, Heijde D van der, Landewé R, et al. Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients with Ankylosing Spondylitis: A Randomized Clinical Trial. Arthritis Rheum 2005;52(6):1756-65
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kiltz U, Heldmann F, et al. Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? - a Prospective Study Including Magnetic Resonance Imaging. Arthritis Rheum 2014;66(Suppl):2940
   Google Scholar
• Dougados M, Gueguen A, Nakache JP, et al. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 1999;38:235-44
   PubMed Web of Science ®Google Scholar
• Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford) 2010;49:1317-25
   Google Scholar
• Peloso PM, Gammaitoni A, Smugar SS, et al. Longitudinal Numbers-Needed-To-Treat (NNT) for Achieving Various Levels of Analgesic Response and Improvement with Etoricoxib, Naproxen, and Placebo in Ankylosing Spondylitis. BMC Musculoskelet Disord 2011;12(1):165
   Google Scholar
• Anderson JJ, Baron G, Van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86
   PubMed Web of Science ®Google Scholar
• Zochling J, Bohl-Buhler MH, Baraliakos X, et al. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis–a population-based survey. Clin Rheumatol 2006;25:794-800
   PubMed Web of Science ®Google Scholar
• Gossec L, Dougados M, Phillips C, et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2008;67:782-8
   Google Scholar
• Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011;70:818-22
   PubMed Web of Science ®Google Scholar
• Baigent C, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ V, Pfeffer MA, et al. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N Engl J Med 2005;352(11):1071-80
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
   PubMed Web of Science ®Google Scholar
• Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Rodríguez LAG. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: Review of epidemiologic studies. J Clin Epidemiol 2002;55:157-63
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369(9560):465-73
   PubMed Web of Science ®Google Scholar
• Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62(6):1592-601
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013;15(Suppl 3):S3
   PubMed Web of Science ®Google Scholar
• Lanas a, Garcia-Rodriguez L a, Polo-Tomas M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009;104:1633-41
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465-74
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-88
   PubMed Web of Science ®Google Scholar
• De Vries HS, Van Oijen MGH, Driessen RJB, et al. Appropriate infliximab infusion dosage and monitoring: Results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71:7-19
   PubMed Web of Science ®Google Scholar
• Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 2010;69:1756-61
   PubMed Web of Science ®Google Scholar
• Yoo IK, Choung RS, Hyun JJ, et al. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy. Yonsei Med J 2014;55:442-8
   Google Scholar
• Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2013;1-9
   Google Scholar
• Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: Data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol 2014;41:47-55
   Google Scholar
• Rossi RE. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014;20(46):17352
   PubMed Web of Science ®Google Scholar
• Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2010;62:764-9
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Zikou AK, Voulgari P V, et al. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 2014;16:R125
   PubMed Web of Science ®Google Scholar
• Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012;66(2):201-11
   Google Scholar
• Sampaio-Barros PD, van der Horst-Bruinsma IE. Adverse effects of TNF inhibitors in SpA: Are they different from RA? Best Pract Res Clin Rheumatol 2014;28(5):747-63
   Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 2013;173(15):1416-28
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72(12):1947-55
   PubMed Web of Science ®Google Scholar
• Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 2014;20(10):1714-21
   PubMed Web of Science ®Google Scholar
• Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2014;13(3):522-530.e2
   Google Scholar
• Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy 2015;7(2):73-87
   PubMed Web of Science ®Google Scholar
• Schreiber S, Luger T, Mittendorf T, et al. [Evolution of biologicals in inflammation medicinendash;biosimilars in gastroenterology, rheumatology and dermatology]. Dtsch Med Wochenschr 2014;139(47):2399-404
   Google Scholar
• Aydin SZ, Karadag O, Filippucci E, et al. Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-alpha antagonist therapy: an ultrasound study. Rheumatology (Oxford) 2010;49:578-82
   PubMed Web of Science ®Google Scholar
• Woo J-H, Lee H-J, Sung I-H, Kim T-H. Changes of Clinical Response and Bone Biochemical Markers in Patients with Ankylosing Spondylitis Taking Etanercept. J Rheumatol 2007;34(8):1753-9
   PubMed Web of Science ®Google Scholar
• Arends S, Van Der Veer E, Groen H, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 2011;38:1644-50
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Hetland ML, Sørensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol 2010;29:1301-9
   PubMed Web of Science ®Google Scholar
• De Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte Sedimentation Rate, C-Reactive Protein Level, and Serum Amyloid a Protein for Patient Selection and Monitoring of Anti-Tumor Necrosis Factor Treatment in Ankylosing Spondylitis. Arthritis Rheum 2009;61(11):1484-90
   PubMedGoogle Scholar
• Méric J-C, Mulleman D, Ducourau E, et al. Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 2011;33:411-16
   Google Scholar
• Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014;12(9):1474-1481.e2. quiz e91
   PubMed Web of Science ®Google Scholar